Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M malaria vaccine safety and immunogenicity study in Thai adults
ISRCTN57717892Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jan 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in malaria comparing R21/Matrix-M + dihydroartemisinin + piperaquine + primaquine, R21/Matrix-M only and dihydroartemisinin + piperaquine + primaquine only (3 arms). Primary endpoints: Solicited adverse events, Unsolicited adverse events and 1 more. Started Jan 2023; status: completed.
02
Drugs
R21/Matrix-Mdihydroartemisininpiperaquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on ISRCTN57717892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57717892.